首页> 美国卫生研究院文献>PLoS Clinical Trials >Rapid Colorimetric Testing for Pyrazinamide Susceptibility of M. tuberculosis by a PCR-Based In-Vitro Synthesized Pyrazinamidase Method
【2h】

Rapid Colorimetric Testing for Pyrazinamide Susceptibility of M. tuberculosis by a PCR-Based In-Vitro Synthesized Pyrazinamidase Method

机译:基于比色法体外合成吡嗪酰胺酶的比色法快速测定结核分枝杆菌的吡嗪酰胺敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug. But PZA susceptibility test is challenging because PZA activity is optimal only in an acid environment that inhibits the growth of M. tuberculosis. For current phenotypic methods, inconsistent results between different labs have been reported. Direct sequencing of pncA gene is being considered as an accurate predictor for PZA susceptibility, but this approach needs expensive sequencers and a mutation database to report the results. An in-vitro synthesized Pyrazinamidase (PZase) assay was developed based on PCR amplification of pncA gene and an in vitro wheat germ system to express the pncA gene into PZase. The activity of the synthesized PZase was used as an indicator for PZA susceptibility. Fifty-one clinical isolates were tested along with pncA sequencing and the BACTEC MGIT 960 methods. The in-vitro synthesized PZase assay was able to detect PZA susceptibility of M. tuberculosis within 24 h through observing the color difference either by a spectrometer or naked eyes. This method showed agreements of 100% (33/33) and 88% (14/16) with the pncA sequencing method, and agreements of 96% (27/28) and 65% (15/23) with the BACTEC MGIT 960 method, for susceptible and resistant strains, respectively. The novel in-vitro synthesized PZase assay has significant advantages over current methods, such as its fast speed, simplicity, no need for expensive equipment, and the potentials of being a direct test, predicting resistance level and easy reading results by naked eyes. After confirmation by more clinical tests, this method may provide a radical change to the current PZA susceptibility assays.
机译:吡嗪酰胺(PZA)是重要的一线抗结核药物。但是PZA敏感性测试具有挑战性,因为PZA活性仅在抑制结核分枝杆菌生长的酸性环境中才是最佳的。对于当前的表型方法,已经报道了不同实验室之间不一致的结果。 pncA基因的直接测序被认为是PZA敏感性的准确预测指标,但是这种方法需要昂贵的测序仪和突变数据库来报告结果。基于pncA基因的PCR扩增和体外小麦胚芽系统,将pncA基因表达为PZase,开发了一种体外合成的吡嗪酰胺酶(PZase)检测方法。合成的PZase的活性用作PZA敏感性的指标。测试了51种临床分离株以及pncA测序和BACTEC MGIT 960方法。体外合成的PZase检测能够通过光谱仪或肉眼观察色差,在24小时内检测结核分枝杆菌的PZA敏感性。该方法显示与pncA测序方法的一致性为100%(33/33)和88%(14/16),与BACTEC MGIT 960方法的一致性为96%(27/28)和65%(15/23)。 ,分别用于易感和抗性菌株。新颖的体外合成PZase测定法具有优于当前方法的显着优势,例如它的速度快,操作简便,不需要昂贵的设备,并且有可能直接测试,预测抗药性水平并易于肉眼阅读结果。经过更多的临床测试确认后,该方法可能会为当前的PZA敏感性测定提供根本性的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号